ArticleMolecular biology reports2026
Antibiofilm activity of Limosilactobacillus fermentum SH2 and Lactococcus lactis extracts against strains of methicillin-resistant Staphylococcus aureus, Staphylococcus hominis SH7, and Pseudomonas aeruginosa.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLactobacillus species are commonly studied probiotic organisms that can inhibit pathogenic bacteria through many mechanisms for the bacterial cells themselves or their extracts, both in vitro and in vivo. METHODS AND
resultsThe inhibitory effects of two lactobacilli species (Limosilactobacillus fermentum SH2 (LF) and Lactococcus lactis subsp. Lactis NRRL1821 (LL)) on the formation of biofilms of methicillin-resistant Staphylococcus aureus ATCC 43,300, Staphylococcus hominis SH7 OM489438, and Pseudomonas aeruginosa ATCC 35,032 were investigated. Molecular analysis of the pathogenic strains revealed that the seb gene is exclusively detected in S. aureus, whereas the icaAA and icaD genes were detected in both S. aureus and S. hominis SH7. Multiple virulence genes, including pslA, pelA, toxA, exoT, exoU, lasB, lasR, and rhlR, were detected in P. aeruginosa. The inhibition of staphylococcal biofilms by Limosilactobacillus fermentum SH2 was distinct, reaching 97.81% inhibition against MRSA, whereas Lactococcus lactis activity increased against P. aeruginosa, with inhibition reaching 98.95%. The results of confocal laser scanning microscopy using acridine orange‒propidium iodide staining demonstrated biofilm disruption and damage to the bacterial membrane. Reverse transcriptase-quantitative polymerase chain reaction analysis demonstrated significant downregulation of the expression of biofilm- and quorum-sensing genes (icaA, icaD, lasR, and rhlR).
conclusionsThese results clearly demonstrated that LAB extracts have antibiofilm activity through membrane disruption, inhibition of the quorum-sensing network, and suppression of genes involved in biofilm formation. These extracts can be developed as alternative strategies for controlling MDR pathogenic bacteria and biofilm-associated infections, as well as reducing the dependence on trivial drugs.
Indexed as
Identifiers
42501208What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.